Source
Medical Product Outsourcing
AccurKardia revealed it’s been granted U.S. Patent No. 12,620,488 for its proprietary machine learning-based system to identify cardiac amyloidosis from a standard, routinely performed 12-lead ECG.
Cardiac amyloidosis occurs when abnormal proteins build up in heart tissue, causing the heart muscle to stiffen and eventually fail. The condition is widely underdiagnosed—most patients are identified only after permanent heart damage has already happened.
Catching it sooner moves patient away from standard heart failure treaments that can be ineffective or even harmful, and toward therapies that are proven to improve survival.
News Url